




## ORIGINAL PAPER

# Prolonged gut microbial alterations in post-transplant survivors of allogeneic haematopoietic stem cell transplantation

Akihisa Hino<sup>1</sup>  | Kentaro Fukushima<sup>1</sup>  | Shinsuke Kusakabe<sup>1</sup>  | Tomoaki Ueda<sup>1</sup> |  
 Takao Sudo<sup>1,2</sup> | Jiro Fujita<sup>1</sup> | Daisuke Motooka<sup>2,3</sup> | Aya K. Takeda<sup>4</sup> |  
 Natsuko O. Shinozaki<sup>4</sup> | Satoshi Watanabe<sup>4</sup> | Takafumi Yokota<sup>1,5</sup> |  
 Hirohiko Shibayama<sup>1,6</sup> | Shota Nakamura<sup>2,3</sup> | Naoki Hosen<sup>1,2,7</sup>

<sup>1</sup>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan

<sup>2</sup>Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Japan

<sup>3</sup>Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Suita, Japan

<sup>4</sup>Cykinso, Inc., Tokyo, Japan

<sup>5</sup>Department of Hematology, Osaka International Cancer Institute, Osaka, Japan

<sup>6</sup>Department of Hematology, National Hospital Organization Osaka National Hospital, Osaka, Japan

<sup>7</sup>Laboratory of Cellular Immunotherapy, World Premier International Immunology Frontier Research Center, Osaka University, Suita, Japan

## Correspondence

Kentaro Fukushima, Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.  
 Email: [kfukushi@bldon.med.osaka-u.ac.jp](mailto:kfukushi@bldon.med.osaka-u.ac.jp)

Shota Nakamura, Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.  
 Email: [nshotat@gen-info.osaka-u.ac.jp](mailto:nshotat@gen-info.osaka-u.ac.jp)

## Summary

Dysbiosis of the gut microbiota has been reported to increase early complications after allogeneic haematopoietic stem cell transplantation (allo-HSCT). However, it remains unclear whether gut microbial alterations persist during late complications, such as chronic graft-versus-host disease (cGVHD) or secondary cancers. Here, we analysed the gut microbiota of 59 patients who survived for 1–21.7 years (median, 6.4 years) after allo-HSCT. Long-term survivors showed lower gut microbial diversity than the age- and sex-matched healthy controls. This decreased diversity was reflected in the reduced abundance of the butyrate-producing bacteria. Patients with a history of grade 3 acute graft-versus-host disease (aGVHD) exhibited higher *Veillonella* abundance than patients with a history of grade 1–2 or non-aGVHD cases. The abundance of *Faecalibacterium* showed no decrease only in limited cGVHD cases. Additionally, the microbial structure in the secondary cancer group was significantly different ( $p < 0.05$ ) from that in the non-secondary cancer group. This study is the first to show that microbial dysbiosis is present over a 10-year lifetime after discharge following allo-HSCT. Our results suggest that these prolonged gut microbial alterations may be associated with the development and exacerbation of late complications in post-transplant survivors.

## KEYWORDS

aGVHD, allogeneic haematopoietic stem cell transplantation, cGVHD, gut microbiota, second cancer

## INTRODUCTION

The outcomes of allogeneic haematopoietic stem cell transplantation (allo-HSCT) have improved with the advent of new therapies and drugs.<sup>1</sup> Such improvements have led to an increase in the number of long-term survivors. Late complications after transplantation are associated with a high mortality rate and decline in quality of life and

represent a major concern for long-term survivors. Chronic graft-versus-host disease (cGVHD) and secondary cancers are particularly concerning.<sup>2,3</sup> cGVHD occurs in 54% of patients following transplantation and accounts for 37.8% of post-transplant, non-relapse mortality.<sup>4,5</sup> The pathogenesis of cGVHD involves uncontrolled B-cell activation, immune activation of specific T-cell subsets, and a deficiency of regulatory T cells.<sup>6</sup>